Alexion and Samsung Bioepis settle German biosimilar lawsuit

Samsung Bioepis’s biosimilar of a drug used to treat a rare blood disorder will remain on the German market
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: